Receptor for advanced glycation end products acts as a fuel to colorectal cancer development

Simple item page
buir.contributor.authorGüre, Ali Osmay
dc.citation.epage24en_US
dc.citation.spage1en_US
dc.citation.volumeNumber10en_US
dc.contributor.authorAzizian-Farsani, F.
dc.contributor.authorAbedpoor, N.
dc.contributor.authorSheikhha, M. H.
dc.contributor.authorGüre, Ali Osmay
dc.contributor.authorNasr-Esfahani, M. H.
dc.contributor.authorGhaedi, K.
dc.date.accessioned2021-02-10T13:45:39Z
dc.date.available2021-02-10T13:45:39Z
dc.date.issued2020-09-29
dc.departmentDepartment of Molecular Biology and Geneticsen_US
dc.description.abstractReceptor for advanced glycation end-products (RAGE) is a multiligand binding and single-pass transmembrane protein taken in diverse chronic inflammatory conditions. RAGE behaves as a pattern recognition receptor, which binds and is engaged in the cellular response to a variety of damage-associated molecular pattern molecules, as well as HMGB1, S100 proteins, and AGEs (advanced glycation end-products). The RAGE activation turns out to a formation of numerous intracellular signaling mechanisms, resulting in the progression and prolongation of colorectal carcinoma (CRC). The RAGE expression correlates well with the survival of colon cancer cells. RAGE is involved in the tumorigenesis, which increases and develops well in the stressed tumor microenvironment. In this review, we summarized downstream signaling cascade activated by the multiligand activation of RAGE, as well as RAGE ligands and their sources, clinical studies, and tumor markers related to RAGE particularly in the inflammatory tumor microenvironment in CRC. Furthermore, the role of RAGE signaling pathway in CRC patients with diabetic mellitus is investigated. RAGE has been reported to drive assorted signaling pathways, including activator protein 1, nuclear factor-κB, signal transducer and activator of transcription 3, SMAD family member 4 (Smad4), mitogen-activated protein kinases, mammalian target of rapamycin, phosphoinositide 3-kinases, reticular activating system, Wnt/β-catenin pathway, and Glycogen synthase kinase 3β, and even microRNAs.en_US
dc.description.provenanceSubmitted by Evrim Ergin (eergin@bilkent.edu.tr) on 2021-02-10T13:45:39Z No. of bitstreams: 1 Receptor_for_advanced_glycation_end_products_acts_as_a_fuel_to_colorectal_cancer_development.pdf: 15960762 bytes, checksum: a564b63b40bc43e88170a6869c7bf814 (MD5)en
dc.description.provenanceMade available in DSpace on 2021-02-10T13:45:39Z (GMT). No. of bitstreams: 1 Receptor_for_advanced_glycation_end_products_acts_as_a_fuel_to_colorectal_cancer_development.pdf: 15960762 bytes, checksum: a564b63b40bc43e88170a6869c7bf814 (MD5) Previous issue date: 2020-09-29en
dc.identifier.doi10.3389/fonc.2020.552283en_US
dc.identifier.issn2234-943X
dc.identifier.urihttp://hdl.handle.net/11693/55052
dc.language.isoEnglishen_US
dc.publisherFrontiers Media S.A.en_US
dc.relation.isversionofhttps://doi.org/10.3389/fonc.2020.552283en_US
dc.source.titleFrontiers in Oncologyen_US
dc.subjectAGEsen_US
dc.subjectAdvanced glycation end productsen_US
dc.subjectCRCen_US
dc.subjectColorectal canceren_US
dc.subjectDamage-associated molecular pattern molecules (DAMPs)en_US
dc.subjectPattern recognition receptor (PRR)en_US
dc.subjectRAGE (receptor for advanced glycation end products)en_US
dc.subjectTumourogenesisen_US
dc.titleReceptor for advanced glycation end products acts as a fuel to colorectal cancer developmenten_US
dc.typeReviewen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Receptor_for_advanced_glycation_end_products_acts_as_a_fuel_to_colorectal_cancer_development.pdf
Size:
15.22 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Scholarly Publications - Molecular Biology and Genetics